Plunkett Research Online: LogicBio Therapeutics Inc

LOGICBIO THERAPEUTICS INC (LOGC:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301......



LogicBio Therapeutics Inc
Ticker: LOGC
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617-245-0399
Fax:
Address: 65 Hayden Avenue
2nd Floor
Lexington, MA 02421 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biological Product (except Diagnostic) Manufacturing
Contacts Description
Frederic Chereau CEO/Director/President
Cecilia Jones CFO/Chief Accounting Officer/Treasurer
See More
LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301......See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
GeneRide
LB-001
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: